Dysregulation of protein kinase C activity in chemoresistant metastatic breast cancer cells

Anti-Cancer Drugs

Volumn 15, Issue 3, 2004, Pages 265-268

  Schöndorf, Thomas ^a   Hoopmann, Markus ^b   Breidenbach, Martina ^c   Rein, Daniel T ^d   Göhring, Uwe Jochen ^e   Becker, Martina ^b   Mallmann, Peter ^b   Kurbacherb, Christian M ^b  

^a UNIVERSITY OF APPLIED SCIENCES   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d Dept of Gynecology and Obstetrics ^*  (Germany)

^e Johanniter Krankenhaus   (Germany)

Author keywords

ATP tumor chemosensitivity assay; Breast cancer; Chemoresistance; Protein kinase C

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; DOXORUBICIN; MITOXANTRONE; PACLITAXEL; PROTEIN KINASE C;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CLINICAL ARTICLE; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FEMALE; HUMANS; MIDDLE AGED; PROTEIN KINASE C; TUMOR CELLS, CULTURED;

EID: 1842427489     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200403000-00011     Document Type: Article

References (23)

1. Masso-Welch PA, Winston JS, Edge S, Darcy KM, Asch H, Vaughan MM, et al. Altered expression and localization of PKC-ε in human breast tumors. Breast Cancer Res Treat 2001; 68:211-223.
2. Kambhampati S, Li Y, Verma A, Sassano A, Majchrzak B, Deb DK, et al. Activation of protein kinase C-delta (PKC-δ) by all-trans-retinoic acid. J Biol Chem 2003; 278:32544-32551.
3. Gupta KP, Ward NE, Gravitt KR, Bergman PJ, O'Brian CA. Partial reversal of multidrug resistance in human breast cancer cells by an N-myristoylated protein kinase C-α pseudosubstrate peptide. J Biol Chem 1996; 271:2102-2111.
4. Gauthier ML, Torretto C, Ly J, Francescutti V, O'Day DH. Protein kinase Cα negatively regulates cell spreading and motility in MDA-MB-231 human breast cancer cells downstream of epidermal growth factor receptor. Biochem Biophys Res Commun 2003; 307: 839-846.
5. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 2003; 22:3205-3212.
6. Mills GB, Lu Y, Fang X, Wang H, Eder A, Mao M, et al. The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Semin Oncol 2001; 28(suppl 16):125-141.
7. Real PJ, Sierra A, De Juan A, Segovia JC, Lopez-Vega JM, Fernandez-Luna JL. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 2002; 21:7611-7618.
8. Yang JM, Chin KV, Hait WN. Interaction of P-glycoprotein with protein kinase C in human multidrug resistant carcinoma cells. Cancer Res 1996; 56:3491-3494.
9. Ratnasinghe D, Phang JM, Yeh GC. Differential expression and activity of phosphatases and protein kinases in adriamycin sensitive and resistant human breast cancer MCF-7 cells. Int J Oncol 1998; 13: 79-84.
10. Budworth J, Gant TW, Gescher A. Co-ordinate loss of protein kinase C and multidrug resistance gene expression in revertant MCF-7/Adr breast carcinoma cells. Br J Cancer 1997; 75:1330-1335.
11. Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, et al. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 1995; 55:5276-5282.
12. Schöndorf T, Becker M, Kolhagen H, Kurbacher CM, Göhring U-J. Ex vivo assays to evaluate the role of protein kinase C in tumor cells of patients with breast cancer. Anticancer Res 2000; 20:5073-5076.
13. Cartree L, Kucera GL. Gemcitabine induces programmed cell death and activates protein kinase C in BG-1 human ovarian cancer cells. Cancer Chemother Pharmacol 1998; 41:403-412.
14. Cragg LH, Andreef M, Feldman E, Roberts J, Murgo A, Winning M, et al. Phase I trial and correlative laboratory studies of bryostatin (NSC 339555) and high-dose 1-β-D-arabinofuranosylcytosine in patients with refractory acute leukemia. Clin Cancer Res 2002; 8:2123-2133.
15. Mohammad RM, Wall NR, Dutcher JA, Al-Katib AM. The addition of byrostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model. Clin Cancer Res 2000; 6:4950-4956.
16. Lara Jr PN, Gandara DR, Longmate J, Gumerlock PH, Lau DH, Edelmann MJ, et al. Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial. Cancer Chemother Pharmacol 2001; 48:22-28.
17. Teicher BA, Menon K, Alvarez E, Galbreath E, Shih C, Faul M. Antiangiogenic and antitumor effects of a protein kinase C β inhibitor in human T98G glioblastoma multiforme xenografts. Clin Cancer Res 2001; 7:634-640.
18. Teicher BA, Menon K, Alvarez E, Liu P, Shih C, Faul MM. Antiangiogenic and antitumor effects of a protein kinase C β inhibitor in human hepatocellular and gastric cancer xenografts. In Vivo 2001; 15:185-193.
19. Teicher BA, Menon K, Alvarez E, Galbreath E, Shih C, Faul MM. Antiangiogenic and antitumor effects of a protein kinase C β inhibitor in human HT-29 colon carcinoma and human CaKi1 renal cell carcinoma xenografts. Anticancer Res 2001; 21:3175-3184.
20. Boyan BD, Sylvia VL, Frambach T, Lohmann CH, Dietl J, Dean DD, et al. Estrogen-dependent rapid activation of protein kinase C in estrogen receptor-positive MCF-7 breast cancer cells and estrogen receptor-negative HCC38 cells is membrane-mediated and inhibited by tamoxifen. Endocrinology 2003; 144:1812-1824.
21. Zaugg K, Rocha S, Resch H, Hegyi I, Oehler C, Glanzmann C, et al. Differnetial p53-dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase C-specific inhibitor PKC412. Cancer Res 2001; 61:732-738.
22. Rao CV, Simi B, Hirose Y, Upadhyaya P, El-Bayoumy K, Reddy BS. Mechanisms in the chemoprevention of colcon cancer: modulation of protein kinase C, tyrosine protein kinase and diacylglycerol kinase activities by 1,4-phenylenebis-(methylene)selenocyanate and impact of low-fat diet. Int J Oncol 2000; 16:519-527.
23. Kohn EC, Liotta LA. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res 1995; 55:1856-1862.